Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Therapeutics for Pressure Ulcer_EyeGene Inc.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
EGT022 (human derived recombinant polypeptide) / Pressure sore...
Contact Yong U Kim
Participants
You
Email me a copy of this message

Introduction


EG-Decorin (compound name: EGT022), a topical ointment for pressure sore and diabetic foot ulcer, induces rapid repair of damaged capillaries. Thus, it promotes enhanced wound healings. EG-Decorin is majorly composed of human-derived protein ADAM-15 and repairs capillaries via recruiting the pericytes. EG-Decorin may be used with growth factor (GF); steroid may be added without GF to promote its efficacy.


In the molecular aspect, EGT022 is a RGD motif containing recombinant polypeptide from human derived protein ADAM-15. EGT022 has a molecular weight of 6.1- kDa and composed of over 58 amino acids.


EGT022 is an approved therapeutic agent for chronic ischemic disorders such as pressure sore and diabetic foot ulcer.


Development Summary


EG-Decorin induces accelerated wound closure and replacement of granulation tissue in pressure sore model induced normal, diabetic, steroid treated, and old aged mice.


EG-Decorin improves proliferative activities of epidermal cells in rabbit full-thickness ear wound model.


EG-Decorin does not induce skin contraction on the wound lesion during wound healing.


EG-Decorin improves microvascular disorders caused by ischemia-reperfusion cycles.


EG-Decorin promotes stabilization and maturation of impaired vessels in wounded lesions.


Expression system in Pichia pastoris and 250L production and purification process is established.


 

Type of Business Relationship Sought
Co-development and Licensing Out
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
GOVERNMENT INSTITUTE